1304. Infection Control
Session: Symposium: Critical Collaborations in Antimicrobial Stewardship, Infection Control, and Diagnostic Microbiology
Saturday, October 20, 2012: 11:00 AM
Room: SDCC 25 ABC
Formal antimicrobial stewardship committees are becoming increasingly common in healthcare settings.  The role of infection control in antimicrobial stewardship is often misunderstood, poorly defined and confusing.  This talk with focus on the synergistic roles that infection control can support in antimicrobial stewardship. Clinical, quality improvement and administrative opportunities will be discussed.
Keith Kaye, MD, MPH, FIDSA, FSHEA, Wayne State University, Detroit, MI

Dr. Kaye is a Professor of Medicine in the Division of Infectious Diseases and Department of Medicine at Wayne State University and Detroit Medical Center. He is the Corporate Medical Director of Hospital Epidemiology and Antimicrobial Stewardship at Detroit Medical Center and Wayne State University. Dr. Kaye’s particular academic interests and skills are epidemiology of and outcomes associated with multi-drug resistant bacteria; infections in the elderly; surgical site infection; device-related infections and antimicrobial stewardship. Dr. Kaye oversees all Infection Prevention and Antibiotic Stewardship-related activities at Detroit Medical Center, an 8 hospital health system that has over 2000 beds and that includes both community and tertiary care hospitals Dr. Kaye received his medical degree from the University of Pennsylvania and served his Internal Medicine residency and was an Infectious Diseases fellow at Beth Israel Deaconess Medical Center in Boston, MA. During fellowship, Dr. Kaye earned a Masters in Public Health from the Harvard School of Public Health. Dr. Kaye has authored over 100 peer-reviewed articles and 15 book chapters, including a chapter in Hospital Epidemiology and Infection Control and has presented numerous abstracts at national conferences. Dr. Kaye has been a national leader in infection prevention and antimicrobial stewardship. Dr. Kaye is currently PI on a multi-center NIH-funded contract studying colistin-based therapy for infections due to extremely-drug resistant (XDR)-Gram-negative bacilli.



Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.